Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, and Pharmacokinetics of IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease

NCT07231679 is registered in ClinicalTrials.gov with Ingenia Therapeutics INC as lead sponsor.

NCT NCT07231679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07231679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, and Pharmacokinetics of IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease
Lead sponsor
Ingenia Therapeutics INC
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 30, 2025
Completion date
April 30, 2027
Enrollment
94 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, healthy volunteers